| Publication |
Sentence |
Publish Date |
Extraction Date |
Species |
| Adam Goldman-Yassen, Azalea Lee, Grace Gombola. Leptomeningeal Enhancement in Pediatric Anti-Myelin Oligodendrocyte Glycoprotein Antibody Disease, Multiple Sclerosis, and Neuromyelitis Optica Spectrum Disorder. Pediatric neurology. vol 153. 2024-02-21. PMID:38382244. |
leptomeningeal enhancement in pediatric anti-myelin oligodendrocyte glycoprotein antibody disease, multiple sclerosis, and neuromyelitis optica spectrum disorder. |
2024-02-21 |
2024-02-24 |
Not clear |
| Adam Goldman-Yassen, Azalea Lee, Grace Gombola. Leptomeningeal Enhancement in Pediatric Anti-Myelin Oligodendrocyte Glycoprotein Antibody Disease, Multiple Sclerosis, and Neuromyelitis Optica Spectrum Disorder. Pediatric neurology. vol 153. 2024-02-21. PMID:38382244. |
anti-myelin oligodendrocyte glycoprotein (mog) antibody disease (mogad) is a type of acquired demyelinating disease that is distinct from multiple sclerosis (ms) and aquaporin-4 antibody neuromyelitis optica spectrum disorder (aqp4-nmosd). |
2024-02-21 |
2024-02-24 |
Not clear |
| Susanna Asseyer, Ofir Zmira, Laura Busse, Barak Pflantzer, Patrick Schindler, Tanja Schmitz-Hübsch, Friedemann Paul, Claudia Chie. Regional spinal cord volumes and pain profiles in AQP4-IgG + NMOSD and MOGAD. Frontiers in neurology. vol 15. 2024-02-13. PMID:38343712. |
aquaporin-4-antibody-seropositive (aqp4-igg+) neuromyelitis optica spectrum disorder (nmosd) and myelin oligodendrocyte glycoprotein antibody-associated disorder (mogad) are relapsing neuroinflammatory diseases, frequently leading to chronic pain. |
2024-02-13 |
2024-02-15 |
Not clear |
| Mengyuan Yao, Wenjing Wang, Jiali Sun, Tianshu Guo, Jiangping Bian, Fuyao Xiao, Yuanyuan Li, Hengri Cong, Yuzhen Wei, Xinghu Zhang, Jianghong Liu, Linlin Yi. The landscape of PBMCs in AQP4-IgG seropositive NMOSD and MOGAD, assessed by high dimensional mass cytometry. CNS neuroscience & therapeutics. vol 30. issue 2. 2024-02-09. PMID:38334017. |
data on peripheral blood mononuclear cells (pbmcs) characteristics of aquaporin-4 (aqp4)-igg seropositive neuromyelitis optica spectrum disorder (nmosd) and myelin oligodendrocyte glycoprotein antibody-associated disease (mogad) are lacking. |
2024-02-09 |
2024-02-11 |
Not clear |
| Chiara Rocchi, Mirasol Forcadela, Patricia Kelly, Samantha Linaker, Emily Gibbons, Maneesh Bhojak, Anu Jacob, Shahd Hamid, Saif Hud. The absence of antibodies in longitudinally extensive transverse myelitis may predict a more favourable prognosis. Multiple sclerosis (Houndmills, Basingstoke, England). 2024-01-23. PMID:38258822. |
isolated first episodes of longitudinally extensive transverse myelitis (letm) have typically been associated with neuromyelitis optica spectrum disorder (nmosd) or myelin oligodendrocyte glycoprotein antibody-associated disease (mogad). |
2024-01-23 |
2024-01-25 |
Not clear |
| Lei Wang, Ruihong Xia, Xiangliang Li, Jingli Shan, Shengjun Wan. Systemic inflammation response index is a useful indicator in distinguishing MOGAD from AQP4-IgG-positive NMOSD. Frontiers in immunology. vol 14. 2024-01-23. PMID:38259484. |
to identify reliable immune-inflammation indicators for distinguishing myelin oligodendrocyte glycoprotein antibody-associated disease (mogad) from anti-aquaporin-4 immunoglobulin g (aqp4-igg)-positive neuromyelitis optica spectrum disorders (nmosd). |
2024-01-23 |
2024-01-25 |
Not clear |
| Soumya S Yandamuri, Beata Filipek, Nikhil Lele, Inessa Cohen, Jeffrey L Bennett, Richard J Nowak, Elias S Sotirchos, Erin E Longbrake, Emily M Mace, Kevin C O'Conno. A Noncanonical CD56dimCD16dim/- NK Cell Subset Indicative of Prior Cytotoxic Activity Is Elevated in Patients with Autoantibody-Mediated Neurologic Diseases. Journal of immunology (Baltimore, Md. : 1950). 2024-01-22. PMID:38251887. |
neuromyelitis optica spectrum disorder (nmosd), myelin oligodendrocyte glycoprotein ab disease, and autoimmune myasthenia gravis (mg) are autoantibody-mediated neurologic conditions where autoantibodies can induce ab-dependent cellular cytotoxicity (adcc), a nk cell-mediated effector function. |
2024-01-22 |
2024-01-24 |
Not clear |
| N L Sheremet, D D Eliseeva, A K Kalashnikova, M N Zakharov. [Typical and atypical optic neuritis]. Vestnik oftalmologii. vol 139. issue 6. 2024-01-18. PMID:38235645. |
demyelinating on can be idiopathic or be one of the symptoms of autoimmune demyelinating diseases of the central nervous system (cns) such as multiple sclerosis (ms), neuromyelitis optica spectrum disorders (nmosd), myelin oligodendrocyte glycoprotein antibody-associated disease (mogad). |
2024-01-18 |
2024-01-20 |
Not clear |
| Giordani Rodrigues Dos Passos, Tarso Adoni, Maria Fernanda Mendes, Douglas Kazutoshi Sat. Reshaping neuroimmunology: diagnosis and treatment in the era of precision medicine. Arquivos de neuro-psiquiatria. vol 81. issue 12. 2023-12-29. PMID:38157878. |
this review explores the impact of precision medicine on various neuroimmunological conditions, including multiple sclerosis (ms), neuromyelitis optica spectrum disorder (nmosd), myelin oligodendrocyte glycoprotein antibody-associated disease (mogad), optic neuritis, autoimmune encephalitis, and immune-mediated neuropathies. |
2023-12-29 |
2024-01-05 |
Not clear |
| Stephanie B Syc-Mazurek, John J Chen, Pearse Morris, Elia Sechi, Jaywant Mandrekar, Jan-Mendelt Tillema, A Sebastian Lopez-Chiriboga, Claudia Francesca Lucchinetti, Nicholas Zalewski, Laura Cacciaguerra, Marina Buciuc, Karl N Krecke, Steven Anthony Messina, M Tariq Bhatti, Sean J Pittock, Eoin P Flanaga. Frequency of New or Enlarging Lesions on MRI Outside of Clinical Attacks in Patients With MOG-Antibody-Associated Disease. Neurology. vol 99. issue 18. 2023-12-19. PMID:36175150. |
to determine the frequency of new or enlarging t2-hyperintense or enhancing lesions outside of clinical attacks in myelin oligodendrocyte glycoprotein antibody-associated disease (mogad) vs multiple sclerosis (ms) and aquaporin-4 antibody positive neuromyelitis optica spectrum disorder (aqp4+nmosd). |
2023-12-19 |
2023-12-21 |
Not clear |
| Ankelien Duchow, Judith Bellmann-Strobl, Tim Friede, Orhan Aktas, Klemens Angstwurm, Ilya Ayzenberg, Achim Berthele, Eva Dawin, Daniel Engels, Katinka Fischer, Martina Flaskamp, Katrin Giglhuber, Matthias Grothe, Joachim Havla, Martin W Hümmert, Sven Jarius, Matthias Kaste, Peter Kern, Ingo Kleiter, Luisa Klotz, Mirjam Korporal-Kuhnke, Markus Kraemer, Markus Krumbholz, Tania Kümpfel, Lisa Lohmann, Marius Ringelstein, Paulus Rommer, Patrick Schindler, Charlotte Schubert, Carolin Schwake, Makbule Senel, Florian Then Bergh, Daria Tkachenko, Hayrettin Tumami, Corinna Trebst, Ioannis Vardakas, Annette Walter, Clemens Warnke, Martin S Weber, Jonathan Wickel, Brigitte Wildemann, Alexander Winkelmann, Friedemann Paul, Jan-Patrick Stellmann, Vivien Häußle. Time to disability milestones and annualized relapse rates in NMOSD and MOGAD. Annals of neurology. 2023-12-12. PMID:38086777. |
to investigate accumulation of disability in neuromyelitis optica spectrum disorder (nmosd) and myelin oligodendrocyte glycoprotein-antibody-associated disease (mogad) in a changing treatment landscape. |
2023-12-12 |
2023-12-17 |
Not clear |
| Miyo K Chatanaka, Lisa M Avery, Maria D Pasic, Shanthan Sithravadivel, Dalia Rotstein, Catherine Demos, Rachel Cohen, Taron Gorham, Mingyue Wang, Martin Stengelin, Anu Mathew, Jacob Wohlstadter, Ioannis Prassas, Eleftherios P Diamandi. The relationship between serum astroglial and neuronal markers and AQP4 and MOG autoantibodies. Research square. 2023-12-11. PMID:38077014. |
background certain demyelinating disorders, such as neuromyelitis optica spectrum disorder (nmosd) and myelin oligodendrocyte glycoprotein antibody-associated disease (mogad) exhibit serum autoantibodies against aquaporin-4 (αaqp4) and myelin oligodendrocyte glycoprotein (αmog). |
2023-12-11 |
2023-12-17 |
Not clear |
| Katharina Messias, Renata Moreto, Camila Aquino Cruz, Nathalia Rossoni Ronchi, Antonio Carlos Dos Santos, André Messias, Vanessa Daccach Marque. Clinical spectrum of myelin oligodendrocyte glycoprotein antibody-associated disease in Brazil: a single-center experience. Arquivos de neuro-psiquiatria. vol 81. issue 11. 2023-11-30. PMID:38035583. |
anti-myelin oligodendrocyte glycoprotein (anti-mog) antibody-associated disease (mogad) is an immune-mediated neurological disorder with a broad spectrum of clinical presentation that is often difficult to distinguish from other demyelinating diseases, such as multiple sclerosis and neuromyelitis optica spectrum disorder. |
2023-11-30 |
2023-12-10 |
Not clear |
| A N Belova, G E Sheiko, E M Rakhmanova, A N Boyk. [Clinical features and modern diagnostic criteria of the disease associated with myelin oligodendrocyte glycoprotein antibody disease]. Zhurnal nevrologii i psikhiatrii imeni S.S. Korsakova. vol 123. issue 11. 2023-11-23. PMID:37994888. |
demyelinating disease of the central nervous system associated with antibodies to myelin oligodendrocyte glycoprotein (mogad) has been proposed to be distinguished from neuromyelitis optica spectrum disorders (nmosd) into a separate nosological form. |
2023-11-23 |
2023-11-29 |
Not clear |
| James B Davis, Amanda D Henderson, Andrew R Care. Big Data Analysis of Inflammatory Conditions Associated With Optic Neuritis. Journal of neuro-ophthalmology : the official journal of the North American Neuro-Ophthalmology Society. 2023-11-22. PMID:37991878. |
on can be associated with other systemic inflammatory conditions including sarcoidosis, neuromyelitis optica spectrum disorder (nmosd), myelin oligodendrocyte glycoprotein antibody-associated disease (mogad), and lupus; however, prospective studies to establish risk of on associated with these diseases are lacking. |
2023-11-22 |
2023-11-29 |
Not clear |
| Negar Molazadeh, Tetsuya Akaishi, Gauruv Bose, Shuhei Nishiyama, Tanuja Chitnis, Michael Lev. Progression independent of relapses in aquaporin4-IgG-seropositive neuromyelitis optica spectrum disorder, myelin oligodendrocyte glycoprotein antibody-associated disease, and multiple sclerosis. Multiple sclerosis and related disorders. vol 80. 2023-11-10. PMID:37949025. |
progression independent of relapses in aquaporin4-igg-seropositive neuromyelitis optica spectrum disorder, myelin oligodendrocyte glycoprotein antibody-associated disease, and multiple sclerosis. |
2023-11-10 |
2023-11-20 |
Not clear |
| Negar Molazadeh, Tetsuya Akaishi, Gauruv Bose, Shuhei Nishiyama, Tanuja Chitnis, Michael Lev. Progression independent of relapses in aquaporin4-IgG-seropositive neuromyelitis optica spectrum disorder, myelin oligodendrocyte glycoprotein antibody-associated disease, and multiple sclerosis. Multiple sclerosis and related disorders. vol 80. 2023-11-10. PMID:37949025. |
to determine whether progression independent of relapse activity (pira) is present in aquaporin4-igg-seropositive neuromyelitis optica spectrum disorder (aqp4+nmosd), myelin oligodendrocyte glycoprotein antibody-associated disease (mogad) and relapsing remitting multiple sclerosis (rrms). |
2023-11-10 |
2023-11-20 |
Not clear |
| Jonathan D Krett, Marvin J Fritzler, Katayoun Alikhani, Jodie M Burto. A Quality Assessment of Aquaporin-4 & Myelin Oligodendrocyte Glycoprotein Antibody Testing. The Canadian journal of neurological sciences. Le journal canadien des sciences neurologiques. vol 50. issue 6. 2023-10-23. PMID:36398407. |
accurate anti-aquaporin-4 (aqp4) and anti-myelin oligodendrocyte glycoprotein (mog) autoantibody assays are needed to effectively diagnose neuromyelitis optica spectrum disorder and mog antibody-associated disease. |
2023-10-23 |
2023-11-08 |
Not clear |
| Emilie Bergeron, Marc A Bouffar. Evidence-based management of optic neuritis. Current opinion in ophthalmology. 2023-10-17. PMID:37846574. |
optic neuritis can result from several distinct causes, including multiple sclerosis (ms), neuromyelitis optica spectrum disorder (nmosd), and myelin oligodendrocyte glycoprotein antibody disease (mogad), when not idiopathic. |
2023-10-17 |
2023-11-08 |
Not clear |
| Wei Chen, Haojun Yu, Yong Hao, Wanshan Liu, Ruimin Wang, Yida Huang, Jiao Wu, Lei Feng, Yangtai Guan, Lin Huang, Kun Qia. Comprehensive Metabolic Fingerprints Characterize Neuromyelitis Optica Spectrum Disorder by Nanoparticle-Enhanced Laser Desorption/Ionization Mass Spectrometry. ACS nano. 2023-10-11. PMID:37818994. |
timely screening of neuromyelitis optica spectrum disorder (nmosd) and differential diagnosis from myelin oligodendrocyte glycoprotein associated disorder (mogad) are the keys to improving the quality of life of patients. |
2023-10-11 |
2023-10-15 |
human |